Delphi has been legal advisor to AddLife AB when listing on Nasdaq Stockholm.

AddLife AB is a leading independent Nordic player within Life Science with an estimated annual sale of approximately SEK 1.7 billion. AddLife has 25 subsidiaries and 450 employees in the Nordic countries. Clients are operating in the healthcare, laboratories and research in the private and public sectors. AddLife provides high-quality technology products, services and qualified advice in all Nordic markets.

Skadden advised China Merchants Securities (HK) Co., Limited as the sole sponsor, sole global coordinator, sole bookrunner and sole lead manager in the HK$320 million initial public offering of Sinco Pharmaceuticals Holdings Limited on the Hong Kong Stock Exchange.

DWF advised Redag Crop Protection Ltd on funding to enable it to boost its growth plans. More than USD 2 million was raised from a recent round of fundraising led by Acceleris Capital Limited.

The investment will create up to 20 new science posts at the business, which creates new compounds for the agrochemical industry from a base at the Alderley Park life science complex in Cheshire.

Redag will also be recruiting a Chief Operating Officer and two Non-Executive Directors to its board and management team.

Osborne Clarke has advised Investec Bank plc in its capacity as Nominated Adviser and sole bookrunner on the successful AIM IPO of leading Robotic Process Automation software business, Blue Prism Group plc.

The IPO, which priced this morning, will raise £21 million for the company and the selling shareholders, valuing Blue Prism at £48.5 million. Admission and commencement of dealings will take place on Friday, 18 March 2016.

The Osborne Clarke team was led by ECM Partner Jonathan King, assisted by senior associate Jake Turcan.

Berwin Leighton Paisner (BLP) has recently acted for Pantheon Resources plc, the AIM listed oil and gas exploration and production company, on its placing which targeted $25m but with strong demand raised $30m.  The placing was conducted through an accelerated bookbuild process with Stifel Nicholas Europe acting as bookrunner for the placing. Akin Gump advised Stifel.

This was the first significant raise by an Oil & Gas company of 2016.

Pinsent Masons has advised Cancom SE, one of the leading providers of IT infrastructure and IT services in Germany, on its €66.2 million capital raising.

On 2/3 March 2016, Cancom SE successfully increased its share capital by 10%. The new shares were placed by way of accelerated book building with institutional investors with gross proceeds of €66.2 million. The new shares were placed by Hauck & Aufhäuser Privatbankiers KGaA, Frankfurt am Main/Germany, with institutional investors.

Nexam Chemical Holding AB (publ) whose shares are listed on NasdaqFirst North announced on 11 March 2016 that the company had successfully completed a new issue whereby the company receives gross proceeds of SEK 129 million. The new issue was direct towards Swedish and international institutional investors and was executed through an accelerated bookbuilding-process. The proceeds from the new issue will used to finance continued growth and expansion.

Setterwalls assisted Nexam Chemical Holding AB (publ) in the transaction with a team led by Ola Grahn.

Hong Kong—Dentons advised Union Medical Healthcare Limited, an aesthetic medical service provider in Hong Kong and Greater China which owns the brand DR REBORN, on its initial public offering and the related listing of its shares on the Hong Kong Stock Exchange. The offering consisted of a Hong Kong public offering and a concurrent Rule 144A/Reg S placement and raised aggregate gross proceeds of approximately US$96 million, excluding the over-allotment option.

Simpson Thacher recently represented the international joint lead managers in connection with a follow-on offering of AEON REIT Investment Corporation, which included an international offering to institutional investors pursuant to Rule 144A and Regulation S. The offering raised approximately ¥26 billion (US$228 million) for the issuer, which was used with bank financing towards the acquisition of five new properties. Nomura International plc, Mizuho International plc and J.P. Morgan Securities plc acted as international joint lead managers for the offering.

Shearman & Sterling advised Sinco Pharmaceuticals Holdings Limited (Sinco Pharmaceuticals) on its global offering and initial public offering (IPO) on the Main Board of The Stock Exchange of Hong Kong Limited.  China Merchants Securities (HK) Co., Limited acted as the sole sponsor, sole global coordinator, sole bookrunner and sole lead manager.

Sinco Pharmaceuticals is the third largest provider of marketing, promotion and channel management services in the PRC pharmaceutical industry.